Lundbeck, Lu AF28996, Parkinson’s Disease, Parkinson’s Treatment, Phase Ib, Phase II, DARE2, Clinical Trial, Neurology, Neurodegenerative Disease, Dopamine Agonist

VALBY, Denmark, October 6, 2026 H. Lundbeck A/S (Lundbeck) has announced Phase Ib clinical data for Lu AF28996, an...